University of Vermont

College of Medicine

Vermont Cancer Center

trials_support

Supportive Care Clinical Trials

The Vermont Cancer Center has many trials specifically focused on supportive care.

Status: Active - Recruiting
Study Title:
Phase II Trial of Subcutaneous Methylnaltrexone in the Treatment of Severe Opioid-Induced Constipation in Cancer Patients
Purpose: The purpose of this study is to evaluate the efficacy of methylnaltrexone in relieving opioid-induced constipation in cancer patients at various stages of disease.
ClinicalTrials.gov Identifier: NCT00942968
Primary/Site/Co Investigator: Steven Ades, MD
Contact: Karen Wilson (802) 656-4101
Information: http://clinicaltrials.gov/ct2/show/NCT01004393
Institution Number: M10-064, VCC 0911
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title:
VCC 1012 – Randomized Phase II Pilot Study of Loratadine for the Prevention of Pain Caused by the Granulocyte Colony Stimulating Factor Pegfilgrastim
Purpose: Chemotherapy can decrease the number of white blood cells (neutrophils), which are cells needed to fight infection.  Pegfilgrastim is given by injection under the skin shortly after chemotherapy to encourage the production of white blood cells within the bone marrow faster so that you can better fight dangerous infection.  However, pegfilgrastim has a possible side effect of bone and muscle pain in the back and legs, which can vary from mild to severe.  Presently, doctors are unable to predict who will have this type of pain.  This study is being done to determine how frequently back and leg pain appears after getting pegfilgrastim and to assess the possible effectiveness of loratadine (Claritin®) in improving back and leg pain caused by pegfilgrastim. 
ClinicalTrials.gov Identifier: NCT01311336
Primary/Site/Co Investigator: Farrah Khan, MD
Contact: Karen Wilson (802) 656-4101
Information: http://www.clinicaltrials.gov/ct2/show/NCT01311336?term=NCT01311336&rank=1
Institution Number: CHRMS M11-136, VCC 1012
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title:
VCC 1109 – An Internet-Based Weight Loss and Exercise Intervention for Breast Cancer Survivors: The IWEB Program
Purpose: The purpose of this study is to test the effectiveness of a behavioral weight loss and exercise intervention delivered via the internet at different cancer centers in New England.  The research is being done because many women who are treated for breast cancer are overweight and treatment for breast cancer is often accompanied by weight gain. Individuals who are overweight may be more likely to have their breast cancer come back. Also women who exercise at least three hours a week seem to have less chance of their cancer coming back. The investigators hope to identify an effective weight loss and exercise intervention for breast cancer survivors that can be easily accessed by many people.
ClinicalTrials.gov Identifier: NCT01728506
Primary/Site/Co Investigator: Kim Dittus, MD
Contact: Karen Wilson (802) 656-4101
Information: http://www.clinicaltrials.gov/ct2/show/NCT01728506?term=NCT01728506&rank=1
Institution Number: CHRMS M12-109, VCC 1109
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title:
Skeletal Muscle Function in Cancer
Purpose: Patients suffering from cancers, such as lung or pancreas, often experience significant muscle atrophy. Muscle loss can result in weakness, contribute to fatigue and impair function at diagnosis, during therapy and may continue beyond oncologic treatment.

The long term goal of our research effort is to better understand the nature of skeletal muscle atrophy and dysfunction in patients with cancers associated with weight loss. The immediate purpose of this submission is to obtain preliminary data on a small number of patients to support a larger-scale research study. Specifically, we are interested in evaluating whether individuals with lung and pancreatic cancer experience depletion of myosin in their skeletal muscle and/or any evidence of excessive myosin proteolysis or decreased myosin gene transcription.

ClinicalTrials.gov Identifier: N/A
Primary/Site/Co Investigator: Kim Dittus, MD
Contact: Karen Wilson (802) 656-4101
Information: N/A
Institution Number: CHRMS M11-109, VCC 1011
Protocol Research Type: Investigator Initiated
Status: Active - Closed to Accrual
Study Title:
Exercise Training for the PrEvention of Cancer Thrombosis (EXPECT) Pilot
Purpose: You are being invited to take part in a research study that will help us understand the importance of exercising during chemotherapy to prevent blood clots among cancer patients. 
ClinicalTrials.gov Identifier: NCT01853202
Primary/Site/Co Investigator: Susan G. Lakoski, MD
Contact: Elizabeth Eldridge (802) 656-2178
Information: http://clinicaltrials.gov/ct2/show/NCT01853202?term=NCT01853202&rank=1
Institution Number: M13-171, VCC 1220
Protocol Research Type: Investigator Initiated
Status: Active - Closed to Accrual
Study Title: A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy (MEC).

Purpose: The purpose of this study is to determine whether administration of rolapitant with granisetron and dexamethasone (common anti-emetics used with chemotherapy administration) improves chemotherapy-induced nausea and vomiting (CINV).

ClinicalTrials.gov Identifier: NCT01500226
Primary/Site/Co Investigator: Farrah Khan, MD
Contact: Kate Murray (802) 656-9401
Information: http://clinicaltrials.gov/ct2/show/NCT01500226?term=TS-P04834&rank=1
Institution Number: M12-247
Protocol Research Type: Industry Sponsored

Last modified July 16 2014 03:25 PM